Last reviewed · How we verify

Duvie (LOBEGLITAZONE)

Chong Kun Dang · FDA-approved active Small molecule ✓ Verified May 2026 Quality 17/100

Duvie (generic name: LOBEGLITAZONE) is a Small molecule drug developed by Chong Kun Dang. It is currently FDA-approved for Diabetes mellitus type 2.

Duvie is a small molecule medication used to treat type 2 diabetes mellitus. It is often studied in combination with other medications, such as Januvia, in clinical trials.

At a glance

Generic nameLOBEGLITAZONE
SponsorChong Kun Dang
TargetPeroxisome proliferator-activated receptor gamma
ModalitySmall molecule
Therapeutic areaMetabolic
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Duvie

What is Duvie?

Duvie (LOBEGLITAZONE) is a Small molecule drug developed by Chong Kun Dang, indicated for Diabetes mellitus type 2.

What is Duvie used for?

Duvie is indicated for Diabetes mellitus type 2.

Who makes Duvie?

Duvie is developed and marketed by Chong Kun Dang (see full Chong Kun Dang pipeline at /company/chong-kun-dang).

What is the generic name of Duvie?

LOBEGLITAZONE is the generic (nonproprietary) name of Duvie.

What development phase is Duvie in?

Duvie is FDA-approved (marketed).

What does Duvie target?

Duvie targets Peroxisome proliferator-activated receptor gamma.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing